共 50 条
- [1] Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumabCANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (07) : 1747 - 1756Bureau, MathildeChatellier, ThierryPerennec, TanguyGoronflot, ThomasGreilsamer, CharlotteChene, Anne-LaureAffi, RaafetFrampas, EricBennouna, JaafarPons-Tostivint, Elvire
- [2] Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Aguilar, Elizabeth JimenezRicciuti, BiagioGainor, Justin F.Nishino, MizukiAdeni, Anika E.Subegdjo, SafiyaKhosrowjerdi, SaraPeterson, RachelDigumarthy, SubbaLiu, CorinneSauter, Jennifer L.Rizvi, HiraArbour, Kathryn CeciliaCarter, Brett W.Heymach, JohnAltan, MehmetHellmann, Matthew DavidAwad, Mark M.
- [3] Impact of PD-L1 Expression on the Overall Survival of Patients With Non-small Cell Lung Cancer Treated With Single-agent PembrolizumabIN VIVO, 2024, 38 (05): : 2434 - 2440Svaton, MartinKnetki-Wroblewska, MagdalenaTabor, SylwiaDomecky, PetrVenclicek, OndrejKrejci, JanaDrosslerova, MarieHrnciarik, MichalHricisak, DanielBejckova, AlzbetaFischer, OndrejVitkova, MartinaKrzakowski, Maciej
- [4] First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH studyCANCER MEDICINE, 2020, 9 (07): : 2309 - 2316Amrane, KarimGeier, MargauxCorre, RomainLena, HerveLeveiller, GuillaumeGadby, FlorenceLamy, RegineBizec, Jean-LouisGoarant, EricRobinet, GillesGouva, SylvieQuere, GillesAbgral, RonanSchick, UlrikeBernier, CyrilChouaid, ChristosDescourt, Renaud
- [5] Pembrolizumab monotherapy for PD-L1 ≥50% non-small cell lung cancer, undisputed first choice?ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7Theelen, Willemijn S. M. E.Baas, Paul
- [6] Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancerCANCER MEDICINE, 2021, 10 (20): : 6971 - 6984Imai, HisaoKishikawa, TakayukiMinemura, HiroyukiYamada, YutakaIbe, TatsuyaYamaguchi, OuMouri, AtsutoHamamoto, YoichiroKanazawa, KenyaKasai, TakashiKaira, KyoichiKaburagi, TakayukiMinato, KoichiKobayashi, KunihikoKagamu, Hiroshi
- [7] First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50%FUTURE ONCOLOGY, 2021, 17 (23) : 3007 - 3016Descourt, RenaudChouaid, ChristosPerol, MauriceBesse, BenjaminGreillier, LaurentBylicki, OlivierRicordel, CharlesGuisier, FlorianGervais, RadjSchott, RolandAuliac, Jean-BernardRobinet, GillesDecroisette, Chantal
- [8] Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumabTRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (04) : 1533 - +Banna, Giuseppe LuigiSignorelli, DiegoMetro, GiulioGaletta, DomenicoToma, Alessandro DeCantale, OrnellaBanini, MarcoFriedlaender, AlexPizzutillo, PamelaGarassino, Marina ChiaraAddeo, Alfredo
- [9] Prognostic impact of metastatic sites for pembrolizumab efficacy as first-line therapy in patients with PD-L1 tumour proportion score (TPS) ≥ 50% advanced non-small cell lung cancer: A retrospective multicenter studyANNALS OF ONCOLOGY, 2019, 30Kawachi, H.Tamiya, M.Tamiya, A.Ishii, S.Hirano, K.Matsumoto, H.Yokoyama, T.Ishida, T.Ryota, K.Fujimoto, D.Hosoya, K.Suzuki, H.Hirashima, T.Kanazu, M.Sawa, N.Uchida, J.Morita, M.Makio, T.Hara, S.Kumagai, T.